14 Einträge gefunden

1. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer:The Neoadjuvant WSG-TP-II Randomized Clinical Trial

   1. Gluz, Oleg
   2. Nitz, Ulrike A
   3. Christgen, Matthias
   4. Kuemmel, Sherko
   5. Holtschmidt, Johannes
   6. Schumacher, Johannes
   7. Hartkopf, Andreas

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer:an international pooled analysis of individual patient data from four prospective observational studies

   1. Yamamoto, Yutaka
   2. Yamashiro, Hiroyasu
   3. Schneeweiss, Andreas
   4. Müller, Volkmar
   5. Gluz, Oleg
   6. Klare, Peter
   7. Aktas, Bahriye

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
3. Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial

   1. Graeser, Monika
   2. Gluz, Oleg
   3. Biehl, Claudia
   4. Ulbrich-Gebauer, Daniel
   5. Christgen, Matthias
   6. Palatty, Jenci
   7. Kuemmel, Sherko

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
4. ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer

   1. Grote, Isabel
   2. Bartels, Stephan
   3. Christgen, Henriette
   4. Radner, Martin
   5. Gronewold, Malte
   6. Kandt, Leonie
   7. Raap, Mieke

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer

   1. Nitz, Ulrike A
   2. Gluz, Oleg
   3. Kümmel, Sherko
   4. Christgen, Matthias
   5. Braun, Michael
   6. Aktas, Bahriye
   7. Lüdtke-Heckenkamp, Kerstin

   2022 - Forschungsinformationssystem des UKE
6. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

   1. Nitz, Ulrike
   2. Gluz, Oleg
   3. Graeser, Monika
   4. Christgen, Matthias
   5. Kuemmel, Sherko
   6. Grischke, Eva-Maria
   7. Braun, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
7. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

   1. Gluz, Oleg
   2. Nitz, Ulrike
   3. Kolberg-Liedtke, Cornelia
   4. Prat, Aleix
   5. Christgen, Matthias
   6. Kuemmel, Sherko
   7. Mohammadian, Mohammad Parsa

   2022 - Forschungsinformationssystem des UKE
8. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

   1. Graeser, Monika
   2. Harbeck, Nadia
   3. Gluz, Oleg
   4. Würstlein, Rachel
   5. Zu Eulenburg, Christine
   6. Schumacher, Claudia
   7. Grischke, Eva-Maria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
9. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

   1. Graeser, Monika
   2. Feuerhake, Friedrich
   3. Gluz, Oleg
   4. Volk, Valery
   5. Hauptmann, Michael
   6. Jozwiak, Katarzyna
   7. Christgen, Matthias

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
10. Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

    1. Graeser, Monika
    2. Schrading, Simone
    3. Gluz, Oleg
    4. Strobel, Kevin
    5. Herzog, Christopher
    6. Umutlu, Lale
    7. Frydrychowicz, Alex

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
11. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials: Combined analysis from the WSG ADAPT subtrials

    1. Graeser, Monika
    2. Schrading, Simone
    3. Gluz, Oleg
    4. Strobel, Kevin
    5. Würstlein, Rachel
    6. Kümmel, Sherko
    7. Schumacher, Claudia

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
12. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

    1. Grote, Isabel
    2. Bartels, Stephan
    3. Kandt, Leonie
    4. Bollmann, Laura
    5. Christgen, Henriette
    6. Gronewold, Malte
    7. Raap, Mieke

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
13. San Antonio 2016: Progress on the Long Way to Individualized Treatment of Breast Cancer

    1. Müller, Volkmar
    2. Gluz, Oleg
    3. Pierga, Jean-Yves
    4. Thill, Marc
    5. Rack, Brigitte
    6. Witzel, Isabell

    2017 - Forschungsinformationssystem des UKE
14. HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

    1. Harbeck, Nadia
    2. Beckmann, Matthias W
    3. Rody, Achim
    4. Schneeweiss, Andreas
    5. Müller, Volkmar
    6. Fehm, Tanja
    7. Marschner, Norbert

    2013 - Forschungsinformationssystem des UKE